Income seekers and growth investors often choose between biotech pioneers and diversified pharmaceutical giants. Comparing Amgen (NASDAQ:AMGN) and Johnson & Johnson (NYSE:JNJ) reveals two distinct paths for healthcare investing in 2026. Amgen leverages its expertise in biological medicines to target complex diseases while expanding into rare treatments. Johnson & Johnson provides a broader foundation by combining massive drug development with its leading medical technology division. Both companies aim to provide long-term value, but their risk profiles and financial structures differ significantly. Amgen develops and delivers biological medicines for serious illnesses, focusing on inflammation, oncology, and rare diseases. In its latest annual report, filed for the fiscal year ended Dec. 31, 2025, the company noted that it distributes products primarily through pharmaceutical wholesale distributors. McKesson Corp. (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH) collectively accounted for 77% of gross revenues in 2025. Customer concentration like this adds a layer of risk to the business.
CryptoAlerta — análise de criptomoedas e mercado em tempo real